Natural and Induced T Regulatory Cells in Cancer
Open Access
- 1 January 2013
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 4, 190
Abstract
CD4+Foxp3+ T regulatory (Treg) cells control many facets of immune responses ranging from autoimmune diseases, to inflammatory conditions, and cancer in an attempt to maintain immune homeostasis. Natural Treg (nTreg) cells develop in the thymus and constitute a critical arm of active mechanisms of peripheral tolerance particularly to self antigens. A growing body of knowledge now supports the existence of induced Treg (iTreg) cells which may derive from a population of conventional CD4+ T cells. The fork-head transcription factor (Foxp3) typically is expressed by natural CD4+ Treg cells, and thus serves as a marker to definitively identify these cells. On the contrary, there is less consensus on what constitutes iTreg cells as their precise definition has been somewhat elusive. This is in part due to their distinct phenotypes which are shaped by exposure to certain inflammatory or “assault” signals stemming from the underlying immune disorder. The “policing” activity of Treg cells tends to be uni-directional in several pathological conditions. On one end of the spectrum, Treg cell suppressive activity is beneficial by curtailing T cell response against self-antigens and allergens thus preventing autoimmune diseases and allergies. On the other end however, their inhibitory roles in limiting immune response against pseudo-self antigens as in tumors often culminates into negative outcomes. In this review, we focus on this latter aspect of Treg cell immunobiology by highlighting the involvement of nTreg cells in various animal models and human tumors. We further discuss iTreg cells, relationship with their natural counterpart, and potential co-operation between the two in modulating immune response against tumors. Lastly, we discuss studies focusing on these cells as targets for improving anti-tumor immunity.Keywords
This publication has 136 references indexed in Scilit:
- gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced MelanomaNew England Journal of Medicine, 2011
- Phenotypical and functional specialization of FOXP3+ regulatory T cellsNature Reviews Immunology, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- TIM‐3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokinesEuropean Journal of Immunology, 2009
- Expression of GARP selectively identifies activated human FOXP3+ regulatory T cellsProceedings of the National Academy of Sciences, 2009
- Natural and Adaptive Foxp3+ Regulatory T Cells: More of the Same or a Division of Labor?Immunity, 2009
- Myeloid-derived suppressor cells as regulators of the immune systemNature Reviews Immunology, 2009
- Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanomaProceedings of the National Academy of Sciences, 2007
- Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patientsCancer Immunology, Immunotherapy, 2006
- Regulatory T cells, tumour immunity and immunotherapyNature Reviews Immunology, 2006